171 related articles for article (PubMed ID: 22902100)
1. Comparison of response evaluation criteria in solid tumors with volumetric measurements for estimation of tumor burden in pancreatic adenocarcinoma and hepatocellular carcinoma.
Welsh JL; Bodeker K; Fallon E; Bhatia SK; Buatti JM; Cullen JJ
Am J Surg; 2012 Nov; 204(5):580-5. PubMed ID: 22902100
[TBL] [Abstract][Full Text] [Related]
2. Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma.
Bonekamp D; Bonekamp S; Halappa VG; Geschwind JF; Eng J; Corona-Villalobos CP; Pawlik TM; Kamel IR
Eur J Radiol; 2014 Mar; 83(3):487-96. PubMed ID: 24387824
[TBL] [Abstract][Full Text] [Related]
3. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival.
Panda A; Garg I; Truty MJ; Kline TL; Johnson MP; Ehman EC; Suman G; Anaam DA; Kemp BJ; Johnson GB; Halfdanarson TR; Venkatesh SK; Fidler JL; Goenka AH
AJR Am J Roentgenol; 2021 Sep; 217(3):730-740. PubMed ID: 33084382
[No Abstract] [Full Text] [Related]
4. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.
Riaz A; Miller FH; Kulik LM; Nikolaidis P; Yaghmai V; Lewandowski RJ; Mulcahy MF; Ryu RK; Sato KT; Gupta R; Wang E; Baker T; Abecassis M; Benson AB; Nemcek AA; Omary R; Salem R
JAMA; 2010 Mar; 303(11):1062-9. PubMed ID: 20233824
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
[TBL] [Abstract][Full Text] [Related]
6. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers.
Chapiro J; Duran R; Lin M; Schernthaner RE; Wang Z; Gorodetski B; Geschwind JF
Radiology; 2015 May; 275(2):438-47. PubMed ID: 25531387
[TBL] [Abstract][Full Text] [Related]
7. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602.
Sato Y; Watanabe H; Sone M; Onaya H; Sakamoto N; Osuga K; Takahashi M; Arai Y;
Ups J Med Sci; 2013 Mar; 118(1):16-22. PubMed ID: 23167460
[TBL] [Abstract][Full Text] [Related]
8. Fractal analysis improves tumour size measurement on computed tomography in pancreatic ductal adenocarcinoma: comparison with gross pathology and multi-parametric MRI.
Michallek F; Haouari MA; Dana O; Perrot A; Silvera S; Dallongeville A; Dewey M; Zins M
Eur Radiol; 2022 Aug; 32(8):5053-5063. PubMed ID: 35201407
[TBL] [Abstract][Full Text] [Related]
9. Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembolization.
Lin M; Pellerin O; Bhagat N; Rao PP; Loffroy R; Ardon R; Mory B; Reyes DK; Geschwind JF
J Vasc Interv Radiol; 2012 Dec; 23(12):1629-37. PubMed ID: 23177109
[TBL] [Abstract][Full Text] [Related]
10. Size determination and response assessment of liver metastases with computed tomography--comparison of RECIST and volumetric algorithms.
Rothe JH; Grieser C; Lehmkuhl L; Schnapauff D; Fernandez CP; Maurer MH; Mussler A; Hamm B; Denecke T; Steffen IG
Eur J Radiol; 2013 Nov; 82(11):1831-9. PubMed ID: 22717124
[TBL] [Abstract][Full Text] [Related]
11. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
Bonekamp S; Halappa VG; Geschwind JF; Li Z; Corona-Villalobos CP; Reyes D; Bhagat N; Cosgrove DP; Pawlik TM; Mezey E; Eng J; Kamel IR
Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
[TBL] [Abstract][Full Text] [Related]
12. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
Faivre S; Zappa M; Vilgrain V; Boucher E; Douillard JY; Lim HY; Kim JS; Im SA; Kang YK; Bouattour M; Dokmak S; Dreyer C; Sablin MP; Serrate C; Cheng AL; Lanzalone S; Lin X; Lechuga MJ; Raymond E
Clin Cancer Res; 2011 Jul; 17(13):4504-12. PubMed ID: 21531821
[TBL] [Abstract][Full Text] [Related]
13. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
14. Radiological-pathological correlation study of hepatocellular carcinoma undergoing local chemoradiotherapy and surgery.
Kim JW; Seong J; Park MS; Kim KS; Park YN; Han KH; Keum KC; Lee IJ
J Gastroenterol Hepatol; 2016 Sep; 31(9):1619-27. PubMed ID: 26969151
[TBL] [Abstract][Full Text] [Related]
15. Treatment planning and volumetric response assessment for Yttrium-90 radioembolization: semiautomated determination of liver volume and volume of tumor necrosis in patients with hepatic malignancy.
Monsky WL; Garza AS; Kim I; Loh S; Lin TC; Li CS; Fisher J; Sandhu P; Sidhar V; Chaudhari AJ; Lin F; Deutsch LS; Badawi RD
Cardiovasc Intervent Radiol; 2011 Apr; 34(2):306-18. PubMed ID: 20683722
[TBL] [Abstract][Full Text] [Related]
16. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
[TBL] [Abstract][Full Text] [Related]
17. [Follow-up CT measurement of liver malignoma according to RECIST and WHO vs. volumetry].
Heussel CP; Meier S; Wittelsberger S; Götte H; Mildenberger P; Kauczor HU
Rofo; 2007 Sep; 179(9):958-64. PubMed ID: 17594629
[TBL] [Abstract][Full Text] [Related]
18. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.
Tacher V; Lin M; Duran R; Yarmohammadi H; Lee H; Chapiro J; Chao M; Wang Z; Frangakis C; Sohn JH; Maltenfort MG; Pawlik T; Geschwind JF
Radiology; 2016 Jan; 278(1):275-84. PubMed ID: 26131913
[TBL] [Abstract][Full Text] [Related]
20. Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC?
Vouche M; Salem R; Lewandowski RJ; Miller FH
Abdom Imaging; 2015 Aug; 40(6):1471-80. PubMed ID: 25412868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
